← Leaderboards
Sally E Blank
New York University School Of Medicine
$145,946
Attributed
$145,946
Total exposure
14
Grants
11
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $58.5K · FY2005–08$100K$75K$50K$25K$0
'05
'06
'07
'08
Funding mix
By agency
NIH$145,946 · 14
By mechanism
M01$145,946 · 14
Top collaborators
No co-investigators on record.
Most similar at New York University School Of Medicine
Same institution · by research overlap
- Franco M Muggia$5,360,861
- Sungheon Gene Kim$10,134,654
- Sylvia Adams$1,535,260
- David Zagzag$2,996,633
- John Curtin$59,043
Others in their field
Top investigators on “Funding”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,479,940,681
- Leonard Freedman · Leidos Biomedical Research, Inc.$968,195,877
- Sonia M Thomas · Research Triangle Institute$700,865,642
- David Divins · Consortium For Ocean Leadership, Inc$609,772,544
- Tracy L Nolen · Research Triangle Institute$474,487,152
- Jeffrey P Krischer · University Of South Florida$358,470,093
Research focus
FundingSourceComputer Retrieval Of Information On Scientific Projects DatabaseResourcesUnited States National Institutes Of HealthResearch PersonnelInstitutionGrantResponseTumorToxic EffectCarcinomaOvarianEnd PointIn Complete RemissionEnrollmentMalignant Neoplasm Of OvaryPeritonealSpecimenCarboplatin/PaclitaxelStandards Of Weights And MeasuresPaclitaxelChemotherapyPrevention
Grant awards (16)
CLINICAL TRIAL: GOG-0209: COMPARING TWO REGIMENS IN PATIENTS WITH ENDOMETRIAL CA$3,250
M01 · FY2008 · RR · contact PI
CLINICAL TRIAL: OXALIPLATIN IN COMBINATION WITH PACLITAXEL IN PATIENTS WITH CERV$1,354
M01 · FY2008 · RR · contact PI
CLINICAL TRIAL: OSI 774 WITH CARBOPLATIN AND PACLITAXEL IN OVARIAN OR PERITONEAL$948
M01 · FY2008 · RR · contact PI
GOG-0210: A MOLECULAR STAGING STUDY OF ENDOMETRIAL CARCINOMA$406
M01 · FY2008 · RR · contact PI
GOG-0199: USING SALPINGO-OOPHORECTOMY AND CA-125 TO SCREEN FOR OVARIAN CANCER$406
M01 · FY2008 · RR · contact PI
OSI 774 WITH CARBOPLATIN AND PACLITAXEL IN OVARIAN OR PERITONEAL CARCINOMA$30,772
M01 · FY2007 · RR · contact PI
OXALIPLATIN IN COMBINATION WITH PACLITAXEL IN PATIENTS WITH CERVICAL CANCER$6,312
M01 · FY2007 · RR · contact PI
GOG-0199: USING SALPINGO-OOPHORECTOMY AND CA-125 TO SCREEN FOR OVARIAN CANCER$6,312
M01 · FY2007 · RR · contact PI
OSI 774 WITH CARBOPLATIN AND PACLITAXEL IN OVARIAN OR PERITONEAL CARCINOMA$42,086
M01 · FY2006 · RR · contact PI
OXALIPLATIN IN COMBINATION WITH PACLITAXEL IN PATIENTS WITH CERVICAL CANCER$11,223
M01 · FY2006 · RR · contact PI
GOG-0199: USING SALPINGO-OOPHORECTOMY AND CA-125 TO SCREEN FOR OVARIAN CANCER$5,144
M01 · FY2006 · RR · contact PI
OSI 774 WITH CARBOPLATIN AND PACLITAXEL IN OVARIAN OR PERITONEAL CARCINOMA$24,350
M01 · FY2005 · RR
GOG-0199: USING SALPINGO-OOPHORECTOMY AND CA-125 TO SCREEN FOR OVARIAN CANCER$2,865
M01 · FY2005 · RR
OXALIPLATIN IN COMBINATION WITH PACLITAXEL IN PATIENTS WITH CERVICAL CANCER$2,388
M01 · FY2005 · RR
OSI 774 with Carboplatin and Paclitaxel in Ovarian or Peritoneal Carcinoma$7,368
M01 · FY2004 · RR
GOG-0199: Using Salpingo-oophorectomy and CA-125 to Scr$762
M01 · FY2004 · RR